June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Development of a Moxifloxacin Eluting Hydrogel Patch for Sealing Ocular Lacerations
Author Affiliations & Notes
  • Ann Yung
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Yangcheng Liu
    Department of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, United States
  • Shima Gholizadeh
    Department of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, United States
  • Amirreza Naderi
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Francesca Kahale
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Nasim Annabi
    Department of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, United States
  • Reza Dana
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Ann Yung None; Yangcheng Liu None; Shima Gholizadeh None; Amirreza Naderi None; Francesca Kahale None; Nasim Annabi GelMEDIC Inc., Code I (Personal Financial Interest); Reza Dana GelMEDIX Inc., Code I (Personal Financial Interest)
  • Footnotes
    Support  This work is supported by National Institutes of Health (NIH) (R01EB023052, R01HL140618), Department of Defense Vision Research Program Technology/Therapeutic Development Award (W81XWH-18-1-0654), Research to Prevent Blindness (RPB) Stein Innovation Award and The Tej Kohli Cornea Program at Mass Eye and Ear, located at Mass Eye and Ear, Boston, US.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4149 – F0141. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ann Yung, Yangcheng Liu, Shima Gholizadeh, Amirreza Naderi, Francesca Kahale, Nasim Annabi, Reza Dana; Development of a Moxifloxacin Eluting Hydrogel Patch for Sealing Ocular Lacerations. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4149 – F0141.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Full thickness injuries, in particular full thickness lacerations, render the eye susceptible to infection and vision loss. They are particularly difficult to manage in low resource/emergency settings and repair typically requires extensive surgical skill with high frequency post-operative eyedrop regimens. To address these issues, we have developed a hydrogel sealant with the potential to be used as a rapid repair system to stabilize the globe for laceration type injuries while concurrently permitting sustained drug delivery of an antibiotic, Moxifloxacin (MFX), using a nanoparticle (NP) hydrogel system.

Methods : MXF NPs were synthesized and characterized using dynamic light scattering (DLS) to determine particle diameter (PD) and polydispersity index (PDI), and the encapsulation efficiency (EE) was determined. The sealant, composed of gelatin methacryloyl (GelMA) and glycidyl methacrylate-hyaluronic acid (HAGM), was characterized for degree of methacrylation (DM) and biocompatibility. Lastly, free MFX and MFX NPs were loaded into the hydrogel, and drug release profiles were determined via dialysis. Antimicrobial efficacy was assessed by zone of inhibition studies (ZOI) against a gram + (Staphylococcus Aureus; SA) and gram - (Pseudomonas Aeruginosa; PA) bacteria. The MFX NP hydrogel was further assessed in vitro for sealant capabilities via burst pressure testing.

Results : MFX NPs demonstrated a PD of 221 ± 11 nm, PDI of 0.21 ± 0.02, and EE of 93.8 ± 8.2%. Polymers exhibited a 61% and 11% DM for GelMA and HAGM, respectively, and no signs of cytotoxicity. The drug release profiles showed a 74.7 ± 2.38% and 29.65 ± 2.65% burst release within 2 h, with remaining MFX released within 24 h and 5 days respectively for hydrogels loaded with free MFX and MFX NPs. The MFX NP hydrogel demonstrated high antimicrobial efficacy with a ZOI > 30 mm against PA and > 28 mm for SA over 5 days. Lastly, the MFX NP hydrogel showed a high burst pressure of 40.8 ± 4.2 kPa.

Conclusions : The hydrogel sealant is capable of successfully loading NPs containing antibiotic which allows for efficacious levels of drug release for up to 5 days. Furthermore, it was highly adhesive and able to withstand high levels of pressure. Our drug eluting sealant has the potential to address critical factors in emergency ocular injury care by rapidly restoring the globe and concurrently allowing for efficacious levels of antibiotic to prevent infection.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×